Skip to main content

Address And Details

Mellon Bank Ctr., 1735 Market St.- 37th Fl. , Philadelphia, PA 19103
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Aberdeen International Small Cap Fund (the International Small Cap Fund or the Fund ) seeks long-term growth of capital. The International Small Cap Fund seeks to achieve its objective by investing primarily in equity securities of small non-U.S. companies. Equity securities include, but are not limited to, common stock, preferred stock and depositary receipts. As a non-fundamental policy, under normal market conditions, the Fund will invest at least 80% of the value of its net assets, plus any borrowings for investment purposes, in equity securities of non-U.S. small companies.

Net Asset Value

as of 5:06 PM ET 11/29/2021

Performance

  • 1 Week
  • -2.14%
  • 1 Month
  • -2.85%
  • 3 Months
  • -0.48%
  • 1 Yr Return
  • +25.40%
  • 5 Yr Return
  • +66.75%

Equity Sector Breakdown

Health 24.89%
RetailTrade 17.21%
IndustrialCyclical 16.19%
Technology 11.42%
Services 8.39%
Finance 6.40%
NonDurables 4.02%
ConsumerDurables 1.65%
Energy n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Stocks 97.27%
ForeignStocks 74.06%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
Other 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 112.40 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha 2.53 0.22 -1.61
Beta 0.91 0.87 0.89
R Squared 0.78 0.69 0.67
Std Deviation 19.12 16.11 14.15
Sharpe Ratio 1.22 1.04 n/a

Purchase Information

as of 5:04 PM ET 11/26/2021
Minimum Initial $1000
Minimum Additional $50
Minimum Initial IRA $1000

Performance

Timeframe Average Annual Current Performance Monthly As Of 10/31/2021 Average Annual Current Performance Quarterly As Of 09/30/2021 Avg Annual Current Performance Monthly As Of 10/31/2021 Avg Annual Current Performance Quarterly As Of 09/30/2021
1 Year
  • +41.62%
  • +35.85%
+41.62% +35.85%
3 Year
  • +22.18%
  • +18.21%
+22.18% +18.21%
10 Year
  • +12.32%
  • +12.62%
+12.32% +12.62%
Life Of Fund
  • +8.78%
  • +8.64%
+8.78% +8.64%

Top 10 Holdings

Symbol Company Name % Of Assets
KRNT KORNIT DIGITAL LTD 3.64%
DNP.WA DINO POLSKA SA 3.59%
CYBR CYBERARK SOFTWARE LTD 3.51%
DPH.L DECHRA PHARMACEUTICALS PLC 3.51%
GNS GENUS PLC 3.44%
IPAR INTER PARFUMS 3.41%
HYQGn.DE HYPOPORT AG 3.40%
DAVA ENDAVA PLC 3.05%
BCU.MI BRUNELLO CUCINELLI SPA 2.95%
MTRN.TA MAYTRONICS LTD 2.87%

LATEST NEWS

Recent Articles from TheStreet

Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

5 Top Stock Gainers for Tuesday: ImmunoGen, Immunity Bio, Navigator

ImmunoGen, ImmunityBio, Navigator Holdings, Identiv and Citi Trends are five top stock gainers for Tuesday.

Redbox Instant Is Shutting Down as Verizon Folds Netflix Rival

Wedbush Bullish on Redbox Entertainment, Starts Coverage at Outperform

Redbox can capitalize on its DVD watching loyal customer base to switch to digital and easily clock $1 billion in revenue, said Wedbush.

18 ID4 VW volkswagen 3

Samsung Launches New Auto Chip For Volkswagen, Other Cars

Samsung Electronics announced that it is making three advanced chips tailored specifically for cars.

DiDi Lead

Didi Delisting May Hold Silver Lining for IPO Investors

Crackdown by Beijing on tech companies continues to ramp up.

Activist Barington's Chico's Proxy Fight Could Lead to Sale

Chico's Stock Firms on Unexpected Third-Quarter Profit

Chico's net income registered 15 cents a share in the quarter, obliterating the FactSet analyst consensus of a 3-cent loss.

Under Armour Coronavirus Athletic Mask Lead

NLS Pharmaceutics Soars on Long Covid Fatigue Test Results

NLS says testing of Lauflumide 'offers promise to become a foundational treatment' for Long Covid.

NIO Lead

Nio Stock Drops After Panning Europe Factory Expansion Plans

Nio stock falls after the Chinese luxury electric vehicle maker denies reports that it plans to establish a factory in Europe as part of its expansion plans.

This Proves Nobody Thinks Bull Market in Stocks Dies in 2018

S&P 500 Should Hit 5,000 in First-Half 2022: JPMorgan

'Global supply chain pressures are easing,' JPMorgan says. 'If this persists, the S&P 500 should continue to deliver ... record margins.'

AstraZeneca Lead

AstraZeneca Gains Priorty FDA Review for Breast Cancer Drug

Pharmaceutical titan AstraZeneca announces the FDA has granted priority review for its drug Lynparza used to treat breast cancer after chemotherapy.